Third Rock Ventures LP

This profile gathers the share dealings of Third Rock Ventures LP across 8 companies, led by bluebird bio, Inc., Larimar Therapeutics, Inc. and Agios Pharmaceuticals, Inc. In total, 68 filings cover trades dated from 24 June 2013 to 30 August 2018.

Both buying and selling appear: 2 purchases worth €3.4M, against 13 sales worth €418.0M. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant. Since January 2018: 1 purchase and no sales on the market.

On 4 September 2018 came the latest disclosure, a transaction in Rhythm Pharmaceuticals, Inc. The clock since the last published purchase (24 July 2018) now reads 3,029 days. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.